Generation Bio (NASDAQ:GBIO) Upgraded at Wall Street Zen

Generation Bio (NASDAQ:GBIO) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Friday.

Several other analysts have also recently commented on GBIO. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Generation Bio in a research report on Thursday, May 8th. Wedbush restated an “outperform” rating and issued a $7.00 target price (up from $5.00) on shares of Generation Bio in a research report on Friday.

Generation Bio Trading Down 22.1%

Shares of NASDAQ GBIO opened at $0.41 on Friday. The company has a market cap of $27.24 million, a price-to-earnings ratio of -0.38 and a beta of 2.59. Generation Bio has a 12-month low of $0.30 and a 12-month high of $3.65. The stock’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.53.

Shares of Generation Bio are set to reverse split before the market opens on Tuesday, July 22nd. The 1-10 reverse split was announced on Friday, July 18th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, July 21st.

Generation Bio (NASDAQ:GBIO) last posted its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Generation Bio had a negative return on equity of 75.84% and a negative net margin of 292.92%. The firm had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $1.70 million. As a group, equities analysts forecast that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Generation Bio

Hedge funds have recently modified their holdings of the company. Intech Investment Management LLC acquired a new position in shares of Generation Bio during the 4th quarter valued at $25,000. AQR Capital Management LLC acquired a new position in shares of Generation Bio during the 1st quarter valued at $36,000. EWA LLC acquired a new position in shares of Generation Bio during the 1st quarter valued at $38,000. Nuveen LLC acquired a new position in shares of Generation Bio during the 1st quarter valued at $69,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Generation Bio during the 4th quarter valued at $70,000. 95.22% of the stock is currently owned by institutional investors and hedge funds.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.